Next-Generation Vaccines Advance Through Abu Dhabi DoH and Sanofi’s MoU Agreement at US BIO 2025

At the BIO International Convention 2025 in Boston, the Department of Health Abu Dhabi (DoH), the healthcare regulator for the Emirate, signed a Memorandum of Understanding (MoU) with Sanofi, a global biopharmaceutical company driven by artificial intelligence and innovation. The agreement outlines a strategic partnership aimed at accelerating the development of next-generation vaccines while reinforcing regional capabilities in vaccine manufacturing. By leveraging Abu Dhabi’s growing health-tech ecosystem and advanced research infrastructure, the collaboration seeks to support global R&D efforts and strengthen supply chain resilience across the Middle East. 

MoU to Streamline Regulatory Processes, Enhance Manufacturing, and Promote Expert Collaboration

Abu Dhabi DoH and Sanofi formalized their collaboration with the signing of a Memorandum of Understanding. The signing took place in the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the DoH, and Laurie Gery, Global Head of Business Development, Vaccines at Sanofi. Dr. Asma Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH, and Baptiste de Clarens, General Manager for the Greater Gulf Region, Vaccines at Sanofi, represented their respective organizations during the ceremony.

As part of the agreement, the two parties will work closely to streamline regulatory pathways, strengthen manufacturing capabilities, and foster exchange between local and international experts. The partnership aligns with Abu Dhabi’s broader strategy to position itself as a global hub for biotechnology and pharmaceutical innovation, reinforcing its commitment to forward-looking, technology-enabled healthcare solutions that support both local well-being and global health security.

Dr. Al Mannaei highlighted the partnership’s focus on accelerating vaccine development through the use of advanced technologies, real-time data, and parallel clinical trial phases. By aligning Sanofi’s scientific capabilities with Abu Dhabi’s modern infrastructure, the initiative aims to reduce the time from discovery to public distribution. She noted that the collaboration sets a new standard for innovation, resilience, and global cooperation, and that Abu Dhabi offers a highly connected and purpose-driven environment ideal for advancing impactful healthcare research.

Collaboration to Advance Clinical Research, Optimize Resources, and Leverage mRNA and AI Technologies

In addition, both entities have agreed to collaborate on advancing clinical research and development planning. The partnership includes efforts to optimize resource allocation and establish foundational terms for funding and access. These measures aim to strengthen the healthcare system’s resilience and ensure long-term sustainability, benefiting both the local population and broader global health efforts.

By focusing on more efficient clinical research processes, the collaboration intends to reduce development timelines and improve the speed at which innovative vaccines become available. The agreement also supports equitable access to new treatments.

Sanofi brings to the partnership a strong portfolio of vaccine innovations backed by decades of global experience. The company has played a leading role in the development of vaccines for a wide range of infectious diseases, including influenza, meningitis, and polio. It has also expanded its work in mRNA-based technologies, aiming to create faster, scalable responses to emerging health threats.

In recent years, Sanofi has invested heavily in next-generation vaccine platforms, including its mRNA Center of Excellence and a global AI-driven R&D engine. These initiatives allow the company to design and test vaccine candidates more rapidly and to tailor immune responses for various population groups. This technological capacity supports the goals of the partnership, which include accelerating innovation and strengthening regional preparedness. As stated by de Clarens, “This agreement allows us to examine how Sanofi’s experience in vaccine development could complement Abu Dhabi’s growing R&D ecosystem. Through this initial framework, we look forward to exploring opportunities for public-private collaboration in healthcare innovation.”

Related posts:

US BIO 2025 to Unite 20,000+ Global Biotech Leaders in Boston for Innovation, Policy, and Investment Collaboration South Korean Biotech Command Global Spotlight at BIO 2025 with Dynamic Pavilion & Strategic Alliances BIO 2025: AI Drug Discovery — A Bubble About to Burst, or Reach New Heights? Inside Hong Kong’s Bold Leap to Revolutionize Biotech at US BIO 2025

Author

Denisse Sandoval